Clinical Trial Update: QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial compares QL1706 plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX as first-line treatment for unresectable metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: NOT_YET_RECRUITING